Italy's Chiesi Buys US-Listed KalVista Pharmaceuticals for ...
Chiesi will add KalVista’s hereditary angioedema therapy to its rare disease portfolio, and the drug generated $49 million in 2025 sales.
- On Wednesday, Chiesi Group announced a definitive agreement to acquire KalVista Pharmaceuticals for $27 per share in an all-cash deal valued at approximately $1.9 billion, marking the Italian drugmaker's largest acquisition to date.
- Chiesi aims to bolster its rare disease unit by acquiring Ekterly, KalVista's newly launched oral, on-demand treatment for hereditary angioedema , a genetic disorder characterized by painful swelling attacks traditionally managed through injections.
- Ekterly demonstrated strong market uptake, reaching $49 million in 2025 sales, and Chiesi expects the drug to 'meaningfully contribute' to its 2030 revenue target of €6 billion, up from €3.6 billion in 2025.
- Both companies' boards unanimously approved the transaction, with Chiesi's interim group chief executive Jean-Marc Bellemin stating the deal 'supports our strategy to accelerate impact in rare diseases,' targeting Q3 2026 close.
- KalVista is pursuing label expansion for Ekterly to treat children aged 2 to 11, with an FDA submission planned this year, as competition intensifies from Pharvaris and other companies developing emerging HAE therapies.
15 Articles
15 Articles
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
KalVista Pharmaceuticals (NASDAQ:KALV), a developer of oral therapies for rare diseases, closed Wednesday at $26.67, up 38.62%. The stock moved higher after news that Italy’s Chiesi Group will acquire KalVista for $27 per share in cash. Investors are watching deal closing risks and regulatory approvals. Trading volume reached 69.4 million shares, about 3,323% above its three-month average of 2 million shares. KalVista Pharmaceuticals IPO'd in 20…
Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition
KalVista Pharmaceuticals brings to Chiesi Group the product Ekterly, the first FDA-approved oral drug for acute treatment of swelling attacks from the rare disease hereditary angioedema. Ekterly’s tablet formulation offers a dosing edge compared to injectable HAE medications.
Coverage Details
Bias Distribution
- 70% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
